Analysts’ revenue estimates
Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
Analysts expect the company’s EPS to be $1.31 on revenue of $13.0 billion in the third quarter, a ~5.0% rise compared to $12.4 billion in the third quarter of 2017.
The above chart compares the changes in analysts’ recommendations for Novartis since January.
Analysts expect Novartis to return ~15.5% over the next 12 months. Analysts’ recommendations show a 12-month target price of $98.50 compared to its price of $85.26 on October 8.
Two analysts are tracking Novartis’s ADR (American depositary receipt). Both analysts have given it “strong buy” recommendations. No analysts have given it “holds” or “sells.”
Also, 26 analysts are tracking Novartis stock on the SIX Swiss Exchange. Of these, seven analysts have recommended “strong buys,” eight have recommended “buys,” and 11 have recommended “holds” on the stock. No analysts have recommended “sells.” The consensus rating for Novartis stock stands at 2.15, which represents a “strong buy” for long-term investors.